Patents by Inventor Anthony Pajot

Anthony Pajot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9986721
    Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: June 5, 2018
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Claude Auriault, Véronique Pancre, Yu-Chun Lone, Anthony Pajot, François Lemonnier
  • Publication number: 20170079253
    Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.
    Type: Application
    Filed: July 17, 2012
    Publication date: March 23, 2017
    Inventors: Claude Auriault, Véronique Pancre, Yu-Chun Lone, Anthony Pajot, François Lemonnier
  • Patent number: 9583883
    Abstract: The method for re-establishing the shielding of the cables of a strand on an electrical connector consists, over an annular part situated at one end connected to the connector, in removing only the outer insulating sheath of each shielded cable without stripping the cables of their electromagnetic shield, in grouping the shielded cables together into a strand and in surrounding the strand with an electrically conducting tape forming a sheath re-establishing the shielding of the strand, the sheath re-establishing the shielding being positioned in contact with the electromagnetic shield of the shielded cables and connected to the connector.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 28, 2017
    Assignee: THALES
    Inventors: Olivier Bourgue, Guillaume Prevost, Anthony Pajot
  • Publication number: 20140273630
    Abstract: The method for re-establishing the shielding of the cables of a strand on an electrical connector consists, over an annular part situated at one end connected to the connector, in removing only the outer insulating sheath of each shielded cable without stripping the cables of their electromagnetic shield, in grouping the shielded cables together into a strand and in surrounding the strand with an electrically conducting tape forming a sheath re-establishing the shielding of the strand, the sheath re-establishing the shielding being positioned in contact with the electromagnetic shield of the shielded cables and connected to the connector.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: Olivier BOURGUE, Guillaume PREVOST, Anthony PAJOT
  • Publication number: 20110142911
    Abstract: The invention concerns a peptide comprising an epitope consisting of a sequence of amino acids selected among SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, and having a length not more than 24 amino acids.
    Type: Application
    Filed: August 20, 2007
    Publication date: June 16, 2011
    Applicant: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Yu-Chun Lone, Anthony Pajot
  • Publication number: 20110142862
    Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.
    Type: Application
    Filed: July 5, 2004
    Publication date: June 16, 2011
    Applicant: INSTITUT PASTEUR
    Inventors: Claude Auriault, Veronique Pancre, Yu-Chun Lone, Anthony Pajot, Francois Lemonnier
  • Publication number: 20110067121
    Abstract: The present invention-relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.
    Type: Application
    Filed: December 22, 2009
    Publication date: March 17, 2011
    Inventors: Yu-Chun Lone, Anthony Pajot, Claude Auriault, Veronique Pancre, François Lemonnier
  • Publication number: 20100138936
    Abstract: The invention relates to the use of an expression vector construction coding for the functional HLA-DPal03?401 complex specifically identified by anti-HLA-DP antibodies, in order to create transgenic mice. The invention also relates to the use of the transgenic mice obtained, such as for the comparative preclinical study of the efficacy of vaccine candidates in order to asses the risks associated with the unwanted induction of an autoimmune disease and in order to determine a therapeutic strategy.
    Type: Application
    Filed: March 6, 2006
    Publication date: June 3, 2010
    Inventors: Yu-Chun Lone, Anthony Pajot, François Lemonnier
  • Patent number: 7718259
    Abstract: The invention relates to a composite yarn including a filament yarn of an inorganic or organic material and a matrix of polymer material, the filament yarn being coated, extruded, or incorporated in the polymer material matrix. The matrix includes at least one foamed polymer. A composite yarn is characterized in that it has a core of an above-mentioned composite yarn and is coated, extruded or incorporated in a second polymer material matrix surrounding the core. Various methods may be used for producing the inventive yarns by coating and extrusion.
    Type: Grant
    Filed: November 25, 2004
    Date of Patent: May 18, 2010
    Assignee: Chavanoz Industrie
    Inventors: Laurence Pollet, Violaine Ducru, Stéphane Veran, Anthony Pajot, Stéphanie Lambour
  • Patent number: 7663017
    Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: February 16, 2010
    Assignee: Institut Pasteur
    Inventors: Yu-Chun Lone, Anthony Pajot, Claude Auriault, Veronique Pancre, François Lemonnier
  • Publication number: 20070048523
    Abstract: The invention relates to a composite yarn including a filament yarn of an inorganic or organic material and a matrix of polymer material, the filament yarn being coated, extruded, or incorporated in the polymer material matrix. The matrix includes at least one foamed polymer. A composite yarn is characterized in that it has a core of an above-mentioned composite yarn and is coated, extruded or incorporated in a second polymer material matrix surrounding the core. Various methods may be used for producing the inventive yarns by coating and extrusion.
    Type: Application
    Filed: November 25, 2004
    Publication date: March 1, 2007
    Applicant: CHAVANOZ INDUSTRIE
    Inventors: Laurence Pollet, Violaine Ducru, Stephane Veran, Anthony Pajot, Stephanie Lambour
  • Publication number: 20050114910
    Abstract: The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+?2m°IA?°. The invention also relates to methods of using a transgenic mouse of the invention.
    Type: Application
    Filed: July 2, 2004
    Publication date: May 26, 2005
    Inventors: Yu-Chun Lone, Anthony Pajot, Claude Auriault, Veronique Pancre, Francois Lemonnier